Research map: Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM

Back to the article

Papers in this map

  1. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) · Michael Herdman · 2011 · 10327 citations · Cited by this paper
  2. Pre-shock in acute myocardial infarction: insights from the IABP-SHOCK II and CULPRIT-SHOCK trials · 2026 · Related
  3. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure · C Patrick Green · 2000 · 1845 citations · Cited by this paper
  4. Early SGLT2 inhibition in acute heart failure: when more urine does not necessarily mean better decongestion · 2026 · Related
  5. Hypertrophic Cardiomyopathy · Ali J. Marian · 2017 · 1414 citations · Cited by this paper
  6. Too hot to sleep? Circadian temperature control in heart failure · 2026 · Related
  7. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial · Iacopo Olivotto · 2020 · 1285 citations · Cited by this paper
  8. Cardiac myosin-binding protein C in community-based patients with suspected heart failure · 2026 · Related
  9. Clinical Course and Management of Hypertrophic Cardiomyopathy · Barry J. Maron · 2018 · 946 citations · Cited by this paper
  10. Risk models for sudden cardiac death in cardiomyopathies: clinical, methodological and ethical challenges · 2026 · Related
  11. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines · Steve R. Ommen · 2024 · 726 citations · Cited by this paper
  12. Target Versus Below-Target Dose ACE Inhibitors in U.S. Veterans with HFpEF: Differential Outcomes by CKD Status · 2026 · Related
  13. Genetics of Hypertrophic Cardiomyopathy After 20 Years · Barry J. Maron · 2012 · 714 citations · Cited by this paper
  14. Lower serum chloride levels are associated with worse functional status and higher clinical burden in heart failure · 2026 · Related
  15. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care · John A. Spertus · 2020 · 623 citations · Cited by this paper
  16. Jugular venous ultrasound for the assessment of congestion in the emergency department · 2026 · Related
  17. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers · Robert Lee Anderson · 2018 · 423 citations · Cited by this paper
  18. Rethinking Myocarditis and Genetic Susceptibility in Severe Paediatric Cardiomyopathy · 2026 · Related
  19. Management of Hypertrophic Cardiomyopathy · Barry J. Maron · 2022 · 404 citations · Cited by this paper
  20. Chronotropic response in heart failure: clinical, structural, and metabolic predictors and long-term mortality · 2026 · Related
  21. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores · Nathan S. McClure · 2017 · 360 citations · Cited by this paper
  22. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy · Martin S. Maron · 2024 · 323 citations · Cited by this paper
  23. Development and Validation of a Short Version of the Seattle Angina Questionnaire · Paul S. Chan · 2014 · 307 citations · Cited by this paper
  24. Mechanisms of disease: hypertrophic cardiomyopathy · Norbert Frey · 2011 · 239 citations · Cited by this paper
  25. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial · John A. Spertus · 2021 · 225 citations · Cited by this paper
  26. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy · Martin S. Maron · 2023 · 203 citations · Cited by this paper
  27. Use of the Kansas City Cardiomyopathy Questionnaire for Monitoring Health Status in Patients With Aortic Stenosis · Suzanne V. Arnold · 2012 · 184 citations · Cited by this paper
  28. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy · Chih-Yuan Chuang · 2021 · 179 citations · Cited by this paper
  29. Treatment of Obstructive Hypertrophic Cardiomyopathy Symptoms and Gradient Resistant to First-Line Therapy With β-Blockade or Verapamil · Mark V. Sherrid · 2013 · 178 citations · Cited by this paper
  30. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy · Anne Mette Dybro · 2021 · 174 citations · Cited by this paper
  31. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy · Pablo García‐Pavía · 2024 · 106 citations · Cited by this paper
  32. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy · Pablo García‐Pavía · 2025 · 72 citations · Cited by this paper
  33. Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy · Michael E. Nassif · 2022 · 70 citations · Cited by this paper
  34. Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year · Suzanne V. Arnold · 2018 · 48 citations · Cited by this paper
  35. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) · Mazen A Hanna · 2020 · 44 citations · Cited by this paper
  36. Changing health related quality of life and outcomes in heart failure by age, sex and subtype · Claire Alexandra Lawson · 2023 · 39 citations · Cited by this paper
  37. Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten · Matteo Castrichini · 2024 · 32 citations · Cited by this paper
  38. EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature · Paulina Batóg · 2018 · 26 citations · Cited by this paper
  39. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy · Charles F Sherrod · 2024 · 25 citations · Cited by this paper

Source: OpenAlex (CC0)